

Clonetics™ Cells in Pancreatic Cancer Research

1 April 2014 / Speaker: Andrew Winner 2 April 2014 / Speaker: Dr. Nazim El-Andaloussi

Lonza Cologne GmbH, Cologne / 28 March 2013© Lonza



- Introduction to Pancreatic Cancer
- Differences Between Primary Cells and Cell Lines
- Research Breakthroughs and Challenges
- Benefits of Clonetics[™] Pancreatic Islets
- Custom Products for Pancreatic Research

- Introduction to Pancreatic Cancer
- Differences Between Primary Cells and Cell Lines
- Research Breakthroughs and Challenges
- Benefits of Clonetics[™] Pancreatic Islets
- Custom Products for Pancreatic Research

Pancreatic Cancer Research Market

- Fourth leading cause of cancer deaths¹
- Median survival time < 6 months¹
- Challenging early stage detection
- NCI supports development of new treatments²

- 1. Howard, 1966; Parker, 1996; Greenlee et al., 2000
- 2. Elekta

Pancreatic Cancer Types

- Neuroendocrine tumors (NET)
 - Endocrine cancer Tumorous islets
- Ductal adenocarcinoma
 - Exocrine Cancer
- Acinar cell carcinoma
 - Rare malignant tumor; poor prognosis

Primary Cell Types

Endocrine Region

- Pancreatic islets Alpha, beta cells, delta, PP, Epsilon
- 1 to 2% of pancreas



Exocrine Region

- Acinar, ductal, centroacinar, stem cells
- Acinar cells 85% of pancreas
- Ductal cells 10% of pancreas

- Introduction to Pancreatic Cancer
- Differences Between Primary Cells and Cell Lines
- Research Breakthroughs and Challenges
- Benefits of Clonetics[™] Pancreatic Islets
- Custom Products for Pancreatic Research

Lonza

[Normal] Primary Cells vs. Pancreatic Cell Lines



Concerns About Cell Lines

- NIH authentication of cultured cell lines critical for grant¹
- Some journals mandate characterization before publication
- 18-36% cell lines misidentified or cross-contaminated²
- "Discrepancies exist...for...phenotype and genotype of pancreatic cell lines to warrant careful scrutiny...and thorough application of appropriate controls..."³

^{1.} Notice Number: NOT-OD-08-017 <grants.nih.gov/grants/guide/notice-files/NOT-OD-08-017.html>

^{2.} Hughes P et al. (2007)

^{3.} Pancreas. 2010 May; 39(4): 425-435

- Introduction to Pancreatic Cancer
- Differences Between Primary Cells and Cell Lines
- Research Breakthroughs and Challenges
- Benefits of Clonetics[™] Pancreatic Islets
- Custom Products for Pancreatic Research

Recent Research Breakthroughs

- First Human Model of Cancer Progression PSC's from Pancreatic Cancer Cells¹
- Discovery of cancer stem cells in pancreatic tumors helps understand pancreatic cancer development

Current Research Challenges

- Inconsistent literature on characterization profile of pancreatic cell lines¹
- Limited cell line options for human islets²
- Limited access to normal primary human islets for research use
- Limited access to early-stage donor-cells³
- Isolation difficulties of primary cell types from pancreas⁴

- 1. Pancreas. 2010 May; 39(4): 425-435
- 2. Gordon C. Weir. Clin Invest. 2011;121(9):3395-3397
- 3. Sharon Reynolds.Stem Cells Reveal Secrets About Cancer. http://www.livescience.com/42402-stem-cells-cancer-research-nigms.html
- 4. M.J Smelt et. al. Experimental Diabetes Research Volume 2008 (2008), Article ID 165360, 11 pages

- Introduction to Pancreatic Cancer
- Differences Between Primary Cells and Cell Lines
- Research Breakthroughs and Challenges
- Benefits of Clonetics[™] Pancreatic Islets
- Custom Products for Pancreatic Research



Why Use Clonetics[™] Human Pancreatic Islets?

- Human islet center that manufactures for clinical transplantation
- Fresh and frozen Non-tumorous islets + acinar tissue
- Identity, quantity, purity, & viability testing
- Easy acquisition & steady supply

Why Use Clonetics™ Human Pancreatic Islets?

- Special donor characteristics
- Wilson Wolf Flask
- Growth Media included
- Technical Support

Clonetics™ High-Quality Islets Preparations

Table: Characteristics of islet preparations and outcome of dynamic insulin function assay

		NHP (n=2)	Human (n=3)	AP (n=3)	JP (n=4)
Characteristics of Islet Preparations	Purity (% dithizone stain)	83 ± 11	85 ± 13	90 ± 00	63 ± 19
	OCR/DNA (nmol/min.mg DNA)	221 ± 57 ^h	121 ± 12 ^{nhp,ap,jp}	265 ± 25 ^{h,jp}	188 ± 3.2 ^{a,h,ap}
	Total insulin (pg/ng DNA)	5.9 ± 0.9 ^{jp}	7.8 ± 3.9 ^{jp}	9.2 ± 3.4 ^{jp}	$1.5 \pm 0.8^{hhp,h,ap}$
Insulin Secretory Function (AUC, pg insulin/ ng DNA)	Glucose 1 st + 2 nd phase (16.7 mM)	335 ± 7 ^{ap,jp}	348 ± 85 ^{ap,jp}	121 ± 78 ^{nhp,h,jp}	11.4 ± 4.6 ^{nhp,h,ap}

^a OCR/DNA data were available for 3 of 4 cased in the JP group.

Data are presented as arithmetic means values ± SD.

Statistical significance (P < 0.05): ^{nhp} compared with NHP; ^h compared with human; ^{ap} compared with AP; ^{jp} comapred with JP

Clonetics[™] High-Quality Islets Transduction



Human and mouse islets transduced dsAAV2-eGFP virus
 Transduced islets were able to reverse diabetes *In Vivo*



Clonetics[™] Islets and Western Blots



Rat and human islets were transduced with different recombinant adenoviruses and assessed using immunoblots

Clonetics[™] Fresh Human Pancreatic Islets

Cat. No.	Description	Quantity
00201981	Fresh Human Pancreatic Islets, 100K	>=100,000 IEQ
00201983	Fresh Human Pancreatic Islets, 20K	>=20,000 IEQ
00201984	Fresh Human Pancreatic Islets, 10K	>=10,000 IEQ
00201985	Fresh Human Pancreatic Islets, 5K	>=5,000 IEQ
00202998	Fresh Human Pancreatic Islets, 2K	>=2,000 IEQ

 Special donor characteristics subject to donor availability; turnaround times may vary

Clonetics[™] Fresh Human Pancreatic Islets – Standard QC Testing

Part Number	Test	Minimum Specs Guarantee
Included	Islet Quantity	(IEQ Count)
Included	Islet Sterility	Gram Negative Stain on Day 0
Included	Islet Viability	[FDA/PI] (%) >= 70%
Included	Islet Purity	>= 70% islet cells vs. other tissue (based on visual representation)

COA also includes age, sex, race & BMI of the donor
Islets test negative for Hepatitis B, Hepatitis C & HIV-1



Clonetics[™] Fresh Human Pancreatic Islets – Additional QC Testing

Cat. No.	Test	Typical Results (F.I.O.)	Estimated Testing Time (Results Post-Shipment)
00202551	DNA Quantitation	12.9 +/- 6.9 mg DNA	1 day
00202552	Glucose Stimulated Insulin Response	4.1 +/- 2.8 fold	4 days
00202553	Oxygen Consumption Rate	123.4 +/- 23.1 pmol/min/µg DNA	1 day
00202540	Beta-Cell Composition	48.4 +/- 9.4%	14 days

- Introduction to Pancreatic Cancer
- Differences Between Primary Cells and Cell Lines
- Research Breakthroughs and Challenges
- Benefits of Clonetics[™] Pancreatic Islets
- Custom Products for Pancreatic Research

Cells on Demand™

Human

- Fresh or Frozen Normal Acinar Tissue
- Frozen Normal Islets

Pig, Monkey

Fresh or Frozen Normal Islets and Acinar Tissue

For additional requests not listed above, please contact our Cells on Demand Service **Inquiries:** <u>CellsonDemand@Ionza.com</u>

Lonza Cancer Product Portfolio

- Clonetics[™] and Poietics[™] Cells and Media tested and guaranteed to perform <u>www.lonza.com/primary</u>
 - Primary cells from pancreatic, bone, blood, lymph, lung, mammary and other tissue types
- Nucleofector[™] Technology for transfection of primary cells and cancer cell lines
- Clonetics[™] Conditionally Immortalized Cell Lines (CCICs)
- Biowhittaker[™] Liquid and Powder Media for cancer research and therapeutic applications
- Nucleic Acid and Protein Electrophoresis Products

Summary

- Restricted access to normal primary human islets and limited cell line options for research use
- Lonza's Clonetics[™] Human Pancreatic Islets
 - Fresh or frozen
 - Steady supply
 - Guaranteed quality
 - Flexibility
- Lonza's Cells on Demand[™] Service
 - Acinar tissue
 - Pancreatic cells from animal species

How to Order or Pose Questions

- Order queries:
 - U.S : 800 638 8174 (toll free) or order.us@lonza.com
 - Europe: +32 87 321 611 or order.europe@lonza.com
- Scientific support:
 - U.S: +1 800 521 0390 or <u>scientific.support@lonza.com</u>
 - Europe: +32 87 321 611 or <u>scientific.support.eu@lonza.com</u>
- Web address: <u>www.lonza.com/islets</u> for more information

Interested to Learn More?

- Join our upcoming webinar:
- Efficient Transfection of Biologically Relevant Cells in Immunology Research

Slot 1: Tuesday, 13 May 2014 2 PM EDT (New York) / 11 AM PDT (Los Angeles)

Slot 2: Wednesday, 14 May 2014 10 AM CEST (Berlin) / 9 AM BST (London) / 5 PM JST (Tokyo)

Register at: <u>www.lonza.com/webinar16</u>



Thank You for Your Kind Attention